Shelved Drugs Become a New Research Resource
The National Center for Advancing Translational Sciences, which is the newest branch of the National Institutes of Health, is partnering with big pharma to give academic researchers access to more than 20 drugs that have passed some safety testing in humans but for some reason have been iced by the drug makers.
In a press release, the agency announced that Pfizer, AstraZeneca, and Eli Lilly will make dozens of their compounds available to researchers who will be able to search for new uses for drugs.
NCATS will back the awkwardly named Discovering New Therapeutic Uses for Existing Molecules with $20 million in 2013. According to the release, the companies will provide researchers with the compounds and related data. The partnerships set up by the program will give academics rights to any intellectual property or publications that come from their work with the compounds while the drug makers will retain ownership of the drugs .
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
ChatGPT is going to change education, not destroy it
The narrative around cheating students doesn’t tell the whole story. Meet the teachers who think generative AI could actually make learning better.
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.